Immunotherapy in Pediatric Solid Tumors
The survival rates for pediatric patients with solid tumors have improved dramatically in recent decades. However, patients with metastatic disease at diagnosis or progressive solid tumors still have a poor prognosis. Recently, immunotherapy has emerged as a novel therapeutic strategy in the pediatr...
Main Author: | Jung Yoon Choi |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Pediatric Hematology-Oncology
2020-04-01
|
Series: | Clinical Pediatric Hematology-Oncology |
Subjects: | |
Online Access: | https://doi.org/10.15264/cpho.2020.27.1.22 |
Similar Items
-
Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
by: Jiaqiao Fan, et al.
Published: (2021-01-01) -
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
by: Paris Kosti, et al.
Published: (2018-05-01) -
Advances in Immunotherapy for Adult Glioblastoma
by: Chirayu R. Chokshi, et al.
Published: (2021-07-01) -
Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
by: Lele Miao, et al.
Published: (2021-05-01) -
Chimeric Antigen Receptor-Engineered T Cells in Tumor Immunotherapy: From Bench to Beside
by: Peng WANG
Published: (2017-06-01)